Abstract
In an attempt to define the influence of prior hormonal treatments upon aminoglutethimide activity in advanced cancer of the breast, 42 heavily pretreated postmenopausal patients received aminoglutethimide, 4 × 250 mg daily, with hydrocortisone or cortisone. Twenty-six received high doses of medroxyprogesterone before entering this study. There was no significant difference in patients' characteristics with or without medroxyprogesterone pretreatment. A comparison of patients with and without prior medroxyprogesterone shows a significant difference in the response rate to aminoglutethimide-hydrocortisone (4 vs 32%, P = 0.02). In patients pretreated with tamoxifen but not with medroxyprogesterone the response rate to aminoglutethimide was 36%. These results suggest that aminoglutethimide has a low activity in breast cancer patients previously exposed to medroxyprogesterone, an agent with glucocorticoid-like activity inducing adrenal suppression.
| Original language | English |
|---|---|
| Pages (from-to) | 423-428 |
| Number of pages | 6 |
| Journal | European Journal of Cancer and Clinical Oncology |
| Volume | 21 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 1985 |
Fingerprint
ASJC Scopus subject areas
- Oncology
Cite this
A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma : Low response in patients previously treated with medroxyprogesterone. / Alberto, Pierre; Mermillod, Bernadette; Kaplan, Eli; Goldhirsch, Aron; Obrecht, Jean Pierre; Jungi, Felix; Martz, Georg; Barrelet, Laurent; Cavalli, Franco.
In: European Journal of Cancer and Clinical Oncology, Vol. 21, No. 4, 1985, p. 423-428.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma
T2 - Low response in patients previously treated with medroxyprogesterone
AU - Alberto, Pierre
AU - Mermillod, Bernadette
AU - Kaplan, Eli
AU - Goldhirsch, Aron
AU - Obrecht, Jean Pierre
AU - Jungi, Felix
AU - Martz, Georg
AU - Barrelet, Laurent
AU - Cavalli, Franco
PY - 1985
Y1 - 1985
N2 - In an attempt to define the influence of prior hormonal treatments upon aminoglutethimide activity in advanced cancer of the breast, 42 heavily pretreated postmenopausal patients received aminoglutethimide, 4 × 250 mg daily, with hydrocortisone or cortisone. Twenty-six received high doses of medroxyprogesterone before entering this study. There was no significant difference in patients' characteristics with or without medroxyprogesterone pretreatment. A comparison of patients with and without prior medroxyprogesterone shows a significant difference in the response rate to aminoglutethimide-hydrocortisone (4 vs 32%, P = 0.02). In patients pretreated with tamoxifen but not with medroxyprogesterone the response rate to aminoglutethimide was 36%. These results suggest that aminoglutethimide has a low activity in breast cancer patients previously exposed to medroxyprogesterone, an agent with glucocorticoid-like activity inducing adrenal suppression.
AB - In an attempt to define the influence of prior hormonal treatments upon aminoglutethimide activity in advanced cancer of the breast, 42 heavily pretreated postmenopausal patients received aminoglutethimide, 4 × 250 mg daily, with hydrocortisone or cortisone. Twenty-six received high doses of medroxyprogesterone before entering this study. There was no significant difference in patients' characteristics with or without medroxyprogesterone pretreatment. A comparison of patients with and without prior medroxyprogesterone shows a significant difference in the response rate to aminoglutethimide-hydrocortisone (4 vs 32%, P = 0.02). In patients pretreated with tamoxifen but not with medroxyprogesterone the response rate to aminoglutethimide was 36%. These results suggest that aminoglutethimide has a low activity in breast cancer patients previously exposed to medroxyprogesterone, an agent with glucocorticoid-like activity inducing adrenal suppression.
UR - http://www.scopus.com/inward/record.url?scp=0021813945&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021813945&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(85)90031-8
DO - 10.1016/0277-5379(85)90031-8
M3 - Article
C2 - 3891359
AN - SCOPUS:0021813945
VL - 21
SP - 423
EP - 428
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 4
ER -